Anti-CD34 mab-sirolimus (OrbusNeich)

N/A

Report date: 2026/03/05 13:21:34

Base Information

Drug NameAnti-CD34 mab-sirolimus (OrbusNeich)
Drug Alias NameOrbusNeich Combo StentCombo Dual Therapy Stent
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionSerine/threonine-protein kinase mTOR inhibitorsAnti-CD34
TargetsSerine/threonine-protein kinase mTORHematopoietic progenitor cell antigen CD34
Therapy Area/IndicationsCoronary RestenosisCoronary Artery Disease
Global Approved IndicationsCoronary Restenosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved Date2013/01/01
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesOrbusneich
China Registration ClassN/A

Develop Information

Active CompaniesOrbusneich
Inactive CompaniesN/A
Active IndicationsCoronary Restenosis
Inactive IndicationsCoronary Artery Disease

Other Information

ATC CodeL01XC
Related LinksN/A